Antifungal player F2G banks $60M, eyes IPO in leadup to a PhIII trial
On Monday, as Circassia’s (LSE: $CIR) shares shriveled in value in the wake of a Phase III failure, a pair of UK biotechs raised $123 million to pursue their clinical dreams, underscoring the potential the sector still has in garnering significant sums for therapeutic development work.
One of those companies is Manchester-based F2G, which garnered $60 million to support its development of a new antifungal aimed at the 10% to 30% of patients who don’t respond to the current treatments available. (The other is Verona, a listed company that raised $63 million.)
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.